Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Computer model helps cirrhosis patients get blood thinner doses right faster

NCT ID NCT07571460

Knowledge-focused Sponsor: Kafrelsheikh University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a computer program (Simcyp) could help doctors choose the right starting dose of warfarin, a blood thinner, for 21 patients with liver cirrhosis and a blood clot in the portal vein. The goal was to see if the program helped patients reach a safe, effective level of blood thinning more quickly. The study found that using the program may help achieve the target blood thinning level within a few days, potentially reducing the risk of bleeding or clotting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

21 people

The number who actually took part.

Started

Mar 2024

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Diagnosed liver cirrhosis (Child-Pugh A or B) * Radiologically confirmed portal venous thrombosis * No prior exposure to warfarin (for initial dose simulation) * No pervious history of variceal bleeding Exclusion Criteria: * Child-Pugh C cirrhosis * Platelets \< 50,000/mm³ * Severe renal impairment (eGFR \< 30 mL/min) * Use of strong CYP2C9/CYP3A4 inhibitors or inducers * Pregnancy or breastfeeding * Active malignancy, especially hepatocellular carcinoma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver portal vein thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cirrhosis Portal vein thrombosis

Contacts and locations

Locations

  • Kafrelsheikh University

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.